胶质母细胞瘤
生物
癌症研究
重编程
化学
细胞生物学
缺氧(环境)
糖酵解
谷氨酰胺
胶质瘤
新陈代谢
细胞培养
谷氨酰胺分解
细胞存活
肿瘤细胞
信号转导
医学
作者
Yanhua Qi,Huize Xia,Zijie Gao,Boyan Li,Ziwen Pan,Bowen Feng,Chuanzheng Wang,Weiyang Ma,Ruochuan Li,Jiawei Qiu,Zhe Han,Zheyuan Chen,Weijie Tang,Q. A. Wang,Daiyan Wang,Leyang Hao,Junzhi Liu,Rongrong Zhao,Hongyu Zhao,Gang Li
出处
期刊:癌症:英文版
日期:2026-01-01
卷期号:46: 0066-
标识
DOI:10.34133/cancomm.0066
摘要
Background: Glioblastoma (GBM) is highly refractory to standard therapies, including anti-angiogenic agents such as bevacizumab. While bevacizumab prunes tumor vasculature, it exacerbates intratumoral hypoxia, which drives a metabolically resilient phenotype that limits survival benefits. This study aimed to identify the metabolic dependencies underlying GBM adaptation to hypoxia and to evaluate whether targeting these dependencies could enhance the antitumor efficacy of bevacizumab. Methods: We analyzed the spatial distribution of key metabolites in GBM patients and orthotopic xenograft mouse models using magnetic resonance spectroscopy and chemical shift imaging. A dual-vector hypoxia fate-mapping system paired with an in vivo genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9) knockout screen was employed to identify metabolic vulnerabilities within the hypoxic niche. Metabolic flux was analyzed utilizing 13 C 5 -labeled glutamine tracers. The molecular mechanisms governing solute carrier family 38 member 2 (SLC38A2) regulation were investigated using chromatin immunoprecipitation, cycloheximide chase assays, liquid chromatography–tandem mass spectrometry, and co-immunoprecipitation. The efficacy of targeting SLC38A2 was evaluated through structure-based virtual screening and in vivo orthotopic xenograft models treated concurrently with zonisamide and bevacizumab. Results: Imaging and tissue metabolite analyses revealed a spatial metabolic mismatch in the hypoxic tumor core, characterized by lactate accumulation alongside glutamine depletion. In vivo CRISPR–Cas9 screening identified SLC38A2 as an essential metabolic dependency for GBM cell survival under hypoxic stress. Under hypoxic conditions, hypoxia-inducible factor 1 alpha (HIF-1α) promoted SLC38A2 transcription, while elevated lactate stabilized the SLC38A2 protein through alanyl-tRNA synthetase 1 (AARS1)-mediated lactylation at Lys472. These changes were accompanied by increased glutamine uptake and glutathione biosynthesis, reduced reactive oxygen species levels, and decreased mitochondrial-fission-mediated apoptosis. Pharmacological screening identified the US Food and Drug Administration-approved, brain-penetrant anticonvulsant zonisamide as an inhibitor of SLC38A2. In orthotopic GBM xenograft models, combined treatment with zonisamide and bevacizumab markedly suppressed tumor growth compared with bevacizumab alone. Conclusions: This study defines a spatially organized lactate–glutamine metabolic axis essential for hypoxic adaptation in GBM. The dual transcriptional and posttranslational up-regulation of SLC38A2 represents a critical survival mechanism. This axis can be pharmacologically dismantled by zonisamide, offering a clinically actionable combinational strategy to overcome anti-angiogenic therapy resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI